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Purpose: To develop a niosomal formulation for the delivery of isoniazid to achieve effective treatment 
of tuberculosis.  
Methods: Niosomes were prepared by reverse phase evaporation method and given a charge with a 
charge-inducing agent, dicetyl phosphate. Drug entrapment efficiency in the niosomes was determined 
spectrophotometrically. The niosomes were further characterized for their particle size, polydispersity 
index (PI) and zeta potential as well as by scanning electron microscopy and stability studies. 
Furthermore, in vitro drug release and cellular uptake studies on the niosomes by macrophage J744 A 
were undertaken.  
Results: Suitable isoniazid niosomes were obtained. The niosomes demonstrated a potential to remain 
in the treated site for prolonged periods and were also capable of maintaining steady drug 
concentrations for up to 30 h. Cellular uptake of the drug-loaded niosomes by macrophage cells was as 
high as 61.8 %, a level that is capable of achieving effective treatment of tuberculosis. 
Conclusion: The isoniazid niosomes developed are capable of reducing drug dose and toxicity as well 
as dosing frequency which should bring about improved patient compliance. More importantly, 
macrophage targeting should be feasible at sites where tuberculosis bacteria are harbored. 
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INTRODUCTION 
 
Isoniazid (INH) is an effective drug for the 
treatment of tuberculosis. There is evidence 
that isoniazid (INH) inhibits the synthesis of 
mycolic acid, an essential component of 
bacterial cell wall, and also combines with an 
enzyme that is uniquely found in strains of 
mycobacterium. Resistance to INH can occur 
due to reduction in intracellular penetration of 
the drug.  
Tuberculosis still remains the cause of high 
mortality and morbidity, particularly in 
developing countries. It is curable to a large 
extent but concern about the disease has 
resurfaced due to the emergence of multi-
drug resistant strains and the AIDS pandemic 
[1]. Short-term chemotherapy is associated 
with many disadvantages such as toxicity, 
decreased bioavailability at the target site 
and most important, non-compliance by the 
patient, thus leading to drug resistance. 
Some of the shortcomings of chemotherapy 
can be circumvented by developing a drug 
delivery system that would release the drug 




The concept of using submicron carrier 
systems for the delivery of antibiotics has 
received recognition [3].  For effective 
chemotherapy, an optimal concentration of 
therapeutic agents must reach the affected 
tissue(s) but sometimes, in an attempt to 
achieve,this, serious side effects may occur. 
Niosome is a biodegradable, biocompatible 
and non-immunogenic carrier in which drug 
can be encapsulated. Encapsulation of 
bioactive agent in niosome prevents 
inactivation of the drug, targets the 
biologically active compound to the targeted 
tissue and provides slow release of the 
loaded drug into the circulatory system, 
thereby reducing its toxicity if effective uptake 
is achieved [4].  
 
In earlier studies, antitubercular drugs such 
as INH and rifampicin (RIF) entrapped in PLG 
polymer when injected as a single dose, 
resulted in sustained release of the drug for 6 
- 7 weeks into various organs of mice. The 
pharmacokinetics of PLG-encapsulated 
antitubercular drugs, administered either 







Chemicals and drugs 
 
Span 60 and Span 20 (sorbitan 
monostearate, MW 430.6 and 346.5, 
respectively), cholesterol (MW 386.7), dicetyl 
phosphate (MW 546.9), chloroform, diethyl 
ether, and isniazid (INH, MW 137.1) were all 
obtained from Sigma, St. Louis, USA, while 
RPMI 1640 nutrient broth was procured from 
Sigma-Aldrich. All the other reagents used 
were of analytical grade.  
 
Preparation of niosomes 
 
Drug-containing niosomes were prepared by 
reverse phase evaporation (RPE) method, 
frequently employed for the entrapment of 
hydrophilic drugs [7], using Span 20 or 60 
(SP) as a non-ionic surfactant,  cholesterol 
(CH)  as an enhancer of  niosomal 
membrane rigidity and di-cetylphosphate 
(DCP) as a negative charge inducer [8]. 
Niosomes with varying ratios of these 
materials were prepared (see Table 1). They 
were dissolved (10mg/ml) in a chloroform: 
diethyl ether (1:1) blend (10 ml) in a 100 ml 
round bottom flask to form the organic phase. 
An aqueous phase containing isoniazid 
(10mg/ml) was added, with the ratio of the 
organic phase to aqueous phase ratio fixed at 
5:1. The flask was covered with parafilm to 
prevent evaporation of the organic phase and 
then sonicated with an ultrasonic bath 
sonicator (SN2P, Toschon Industries Pvt Ltd, 
India) at 50 
0
C for 5 min. A stable white 
emulsion was formed from which the organic 
solvents were slowly evaporated at 50 
0
C 
using a rotary vacuum evaporator until a thin 
film was formed on the walls of the flask. The 
film was hydrated with 10 ml of phosphate 
buffer solution (PBS, pH 7.4) to produce an 
aqueous niosomal suspension containing 100 
mg isoniazid/10ml. This suspension was 
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initially kept at 50 
0
C in a thermostatted water 
bath for 1 h and at room temperature over-
night to obtain the drug- niosomes. 
 
Separation of free (un-entrapped) drug  
 
Free (unentrapped) drug was removed from 
the niosomes by centrifugation of the 
dispersion [8] at 14,000 rpm at 4 
0
C for 60 
min in a refrigerated centrifuge (3-18 
K,Sartorius, AG Weender landstrasse, 
Gottingen, Germany). The supernatant was 
removed and the pellet (residue) was re-
suspended in PBS. This process was 
repeated twice to ensure that free drug was 
completely removed. 
 
Particle size determination 
 
The mean size of the particles was measured 
by an optical microscope (CH20i BIMF, 
Olympus India Pvt Ltd) fitted with a camera 
(Yoko CCD Camera, Taiwan) [7]. The particle 
size distribution of each formulation was 
evaluated by determining the size of 100 
randomly selected niosomes with the aid of 
Medical Pro software (version 3.0) 
 
Evaluation of zeta potential and 
polydispersity index (PI) 
 
The surface charge of the niosomes was 
determined by measuring the electrophoretic 
mobility of the niosomal particles using a 
zetasizer (MAL 1021384, Malvern 
Instruments Ltd, UK). Polydispersity index 
was determined as a measure of 
homogeneity. Values were obtained from the 
printed report of Malvern zetasizer which 
includes the percent intensity in terms of size 
distribution of niosomes and their respective 
sizes [8]. Small values of PI indicate a 
homogeneous population while high values 
indicate heterogeneity. 
 
Determination of drug entrapment 
efficiency 
 
Entrapment of isoniazid (INH) in the 
niosomes was determined using a previously 
reported method [8,9]. This method includes 
separation of unentrapped drug using 
Sephadex-75 minicolumn and then 
evaluating the entrapment efficiency by 
disrupting the vesicles with 0.1 % Triton-
X100. The resulting mixture was centrifuged 
at 3000 rpm for 5 min, with the supernatant 
was decanted off and suitably diluted with 
PBS pH 7.4. The drug was estimated 
spectrophotometrically (UV-1700, Shimadzu 
Corporation, Kyoto, Japan) at 261 nm against 
PBS containing Triton-X100 as blank.  
Entrapment efficiency (EE) was determined 
relative to the original drug concentration 
according to Eq 1. 
 
EE (%) =  (ED/TD)100 ……………………   (1)                             
 
where ED is entrapped drug concentration 
and TD is theoretical drug concentration (10 
mg/ml) 
   
Scanning electron microscopy 
 
The morphology of the niosome was studied 
by scanning electron microscopy (SEM, Leo-
430, Cambridge, U.K.). Niosome samples 
were prepared by air-drying on an aluminum 
stub. The stubs were then coated with gold to 
a thickness of 200 to 500 A
0
 under argon 
atmosphere using a gold sputter module in a 
high vacuum evaporator. The coated 
samples were randomly scanned by SEM. 
 
In vitro drug release evaluation 
 
The in vitro drug release profile of the 
isoniazid niosomal formulations was 
assessed by a previously reported method 
[10]. The niosomal formulation was first 
centrifuged to remove un-entrapped drug. 
Next, 1 ml of the niosomal sample was 
packed into a dialysis tube, which in turn was 
placed in a beaker containing 100 ml of PBS 
(pH 7.4). The solution containing the dialysis 
tube (MW cutoff 10,000 Da) was stirred on a 
magnetic stirrer at 50 rpm at 37 ± 1 °C. 
Samples were withdrawn at various time 
intervals over a period of 48 h. Each 
withdrawal was followed by replenishment of 
the release medium with an equal volume of 
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fresh medium to maintain sink conditions. 
The samples were analyzed 
spectrophotometrically for drug content at 
261 nm (Shimadzu 1601, Japan). The tests 
were carried out in triplicate. 
 
Assessment of the physical stability of 
niosomes 
 
Samples of niosomes were sealed in 30 ml 
clear glass vials, stored at 4, 30 and 40 
o
C, 
respectively, for 90 days and assessed 
periodically for changes in particle size and 
residual drug content as previously 
described.  
 
Establishment and maintenance of cell 
line 
 
A mouse macrophage cell line (J744 A.1) 
was grown as a monolayer using RPMI 1640 
media, without glutamine, but supplemented 
with 10 % fetal bovine serum (for nurturing 
the cell line). The media were also 
supplemented with 100 µg/ml each of 
penicillin and streptomycin, to suppress the 
growth of microorganisms. The cell lines 
employed in this study were maintained in a 
humidified incubator at 37 ± 2 
o
C with 95 and 
5% air and CO2, respectively. Cells were sub-
cultured twice weekly by simply re-
suspending the cells using 0.2 and 0.025% 
trypsin and EDTA, respectively, and then 
replacing half of the cell suspension with 
fresh media. Adherent cells were grown to 80 
% confluence in tissue culture grade flasks 
and then subcultured by discarding the used 
medium and leaving the cells which adhered 
to the bottom of the flask. 
 
Viable cell count 
Viable and non-viable cells were 
distinguished using a haemocytometer. For 
this purpose, trypan blue was used. Live cells 
exclude trypan blue stain, leaving them with a 
normal appearance under the microscope. 
Dead cells, however take up the stain, 
making them appear blue. An equal volume 
of cells and stain (0.4 % w/v) were mixed and 
applied to the bright-line haemocytometer. 
The number of cells counted (ignoring blue 
cells) was multiplied by 2 x 10
4 
to calculate 
number of viable cells/ml, thus taking into 
account the dilution factor upon addition of 
trypan blue. 
Cell uptake studies 
 
Calcein-loaded niosomes were prepared to 
study their uptake in J744 A.1 mouse 
macrophage cells. Plain calcein-loaded 
niosome were assayed. The calcein-loaded 
niosomes were prepared by a similar method to 
that used for the drug-loaded niosomes with 
calcein substituted for the drug. The 
concentration of calcein used was 0.5 mg/ml in 
PBS. The calcein-loaded niosomes were 
purified from unloaded calcein niosomes with 
Sephadex G-75 column. 
 
Calcein-loaded niosomes (1 ml) were diluted  in 
1 ml RPMI 1640 media and added to 
monolayers of  J744 A.1 cell lines (2 x 10
5
), 
grown in 96-well culture plate and incubated for 
240 min at 37 ± 2 ºC. The cell monolayers were 
thoroughly washed in PBS and  lysed  in 0.75 
ml of  lysis buffer (PBS containing 0.1% Triton 
X-100). These cells were exposed to serial 
concentrations of the indicated dye (20 - 0.5 
µg/ml of control formulation and 7.5 - 0.5 
µg/ml of coupled formulation in 100 µl of 
culture medium, RPMI 1640 supplemented
 
with 5% heat-inactivated fetal bovine serum) 
over a 3-day incubation period
 
at 37 °C, 5% 
CO2, and 95 % relative humidity.  
 
Their fluorescence was measured in lysis buffer 
extract using florescence activated cell sorter 
(FACS, Becton Dickinson, Gurgaon, Hariyana, 
India) and all the calculations were carried out 
with Cellquest software (version 5.2, BD 




Cells were cultured in 6-well Petri dish with 
1.8 mm cover slips for 24 h. Calcein-loaded 
niosomes were added to the cell culture 
media RPMI 1640 at a concentration of 0.1 
mg/ml. After incubation for 3 h at 37 ºC, the 
cells were washed six times with PBS. The 
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cover slips were put on slides coated with 
buffered mounting medium and viewed with a 
Nikon fluorescence microscope (Japan) [14]. 
 
Statistical analysis:  
 
 
Data, including kinetic data, were processed 
with MS Excel 2007 and are presented as 





Increase in noisome size was observed with 
increase in cholesterol content. In vitro drug 
release of RPE-III-60 was best explained by 
Higuchi equation as the plot showed the 
highest linearity (r
2
 = 0.98), followed by first 
order (r
2
 = 0.97) and zero order (r
2
 = 0.88). 
On the basis of regression coefficient (r
2
) and 
unpaired t-test, the highest r
2
 value was 
obtained for RPE-III-60. Hence, RPE-III-60 
batch was selected for niosomal release 
experiments. Zeta potential for this batch was 
23 mv and while polydispersity index was 
0.14. These values indicate good stability and 
homogeneity of the formulation. The 
corresponding r
2
 (0.98) for the Koresmeyer-
Peppas equation indicate good linearity while 
SEM revealed that the niosomes were 
spherical. Niosome formulations were more 
stable at 4 than at 30 and 40 
o
C (75 ± 5 % 
RH) (Fig 1-3).  
 
 
                 
Fig 1: Electron micrographs of isoniazid niosomes 
(RPE-III-60) 
 
P values for drug release were 0.1578 and 0.6532, respectively.  
 
 
   
(a)            (b) 
 
                                                            
Fig 2: Autoluminicence of (a) calcein-loaded niosomes 
,denoted by P1 peak, and  (b) calcein-loaded niosomes 




Fig 3: Fluorescence image of isoniazid niosomes 
coupled with calcein dye following internalization by 
macrophage cells 
 
A value of 61.8 % was obtained as 
autoluminiscence of calcein-loaded niosomes 
absorbed by macrophage cells denoted by 
P2 peak. 
 
Figure 4 shows that as the proportion of 
cholesterol in the niosomes increased, 
particle size, drug entrapment and t50% (time 
taken to attain 50% drug release) also 
increased. An earlier study had also found 
that incorporation of cholesterol in niosomes 
delayed in vitro drug release [11]. 
 
The regression coefficient (r
2
) when the in 
vitro drug release data were subjected to 
Koresmeyer-Peppas, 1
st
 order, Higuchi and 
zero order release models yielded 0.98, 0.98, 
0.97 and 0.88, respectively for RPE-III-60. 
The release exponent, ‘n’, for the 
Koresmeyer-Peppas model was 0.78, which 
appears to indicate a coupling of diffusion 
and erosion mechanisms. This is the so-
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called anomalous diffusion mechanism, 
which indicates that drug release was 
controlled by more than one process. A value 
of n = 0.45 indicates Fickian diffusion; 0.45 < 
n < 0.89 indicates anomalous (non-Fickian) 
diffusion. 
 
   
 
 
Fig 4: Cumulative release of isoniazid niosomes in 
(a) simulated gastric fluid (pH 1.2), (b) simulated 
intestinal fluid (pH 7.4) where ♦ = RPE III-20 (Batch III 
containing Span-20); ■ = RPE IV-20 (Batch IV 
containing Span-20); ● = RPE III-60 (Batch III 
containing Span-60); ▲ = RPE IV-60 (Batch IV 
containing Span-60)   
 
Cell uptake of niosomes 
 
Cell uptake data indicate that calcein-loaded 
niosomes were taken up easily by J744A.1 
macrophage cell line to a maximum level of 




Increase in particle size was observed upon 
increasing the cholesterol content. 
Entrapment efficiency increased to an 
optimum level on increasing the cholesterol 
level and thereafter decreased. Cholesterol 
(CH) is an important component for changing 
the fluidity of bilayers of niosomes as the 
molecules of the former are sandwiched 
between the molecules of the surfactant (SP) 





On the basis of coefficient of regression (r
2
) 
data, formukation RPE-III-60 was selected as 
the optimum batch [12,13]. On the basis of r
2
 
value, RPE-III-60 and RPE-IV-60 had 
correlation coefficient (R
2
) values close to 
one, i.e., 0.9454 and 0.8621, respectively 
(Table 1). The corresponding plot (log 
cumulative percent drug release vs time) for 
the Koresmeyer-Peppas model indicate good 
linearity (r
2
 = 0.98). The release exponent ‘n’ 
was 0.78, which appears to indicate a 
coupling of diffusion and erosion mechanisms 
(or anomalous diffusion) and may indicate 





At optimum SP:CH ratio (6:3), SP bilayers 
are saturated completely with CH molecules, 
hence no further significant increase in 
vesicle size was observed; however, drug 
entrapment was enhanced. Similarly, di-cetyl 
phosphate (DCP) also affected drug 
entrapment efficiency in the niosomes 
because its incorporation in the bilayers of 
the niosome enhances the vesicle size of the 
niosomes probably due to the identical 
charge in the bilayers, leading to repulsion in 
the bilayers and hence increase in size and 
drug entrapment.  
Negligible degradation and leaching was 
observed at temperature 4 
o
C but significant 
leaching occurred at both 30 and 40 
o
C, 
indicating the need to store the niosomes at 4 
o
C.  
Zeta potential (ZP) of 23 mv and polydis-
persity index (PI) of 0.14 for formulation RPE-
III-60 shows that the formulation was 
homogeneous since PI > 0.3 is indicative of 
A 
B 
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heterogeneity [16]. Ideally, the optimum value 
of zeta potential should lie between +25 and -
25 mv [17]. Outside this range, the niosomes 
may not remain stable for a long period of 
time and this could adversely affect 
parameters such as entrapment efficiency 
and sustained release. A higher zeta 
potential indicates higher kinetic energy and 
tends to move particles towards 
agglomeration [17,18]. 
 
Statistical analysis revealed that there was a 
significant difference between drug release in 
simulated gastric and intestinal fluids. On the 
basis of coefficient of regression (r
2
) data and   




staken as the most suitable isoniazid 
niosomal formulation. 
 
The niosomes obtained in the present work 
released the entrapped drug at steady rate 
for a longer duration (20 - 30 h) than the 10 – 
15 h reported for gliclazide niosomes by other 
researchers [16]. Moreover, the niosomes 
prepared in our work were comparatively 
smaller and more homogenous than the 
gliclazide niosomes. 
 
The fluorescent studies indicate that the 
isoniazid niosomes are capable of remaining 
in treated sites in the body for prolonged 
periods while maintaining constant drug 
concentration in the process. However, 
studies to confirm the extent and duration of 
action of the formulation in vivo were not 
performed. Nonetheless, the isoniazid 
niosomal formulation should improve patient 
compliance as a result of reduced frequency 
of administration could lead to decreased 
dose-dependent side effects often associated 
with repeated administration of conventional 




Isoniazid niosomal formulations are capable 
of facilitating reduced drug dose, dose 
frequency and toxicity when given 
parenterally or via other suitable routes. Their 
use could improve patient compliance and 
most importantly, macrophage targeting 
would be possible at sites where the 
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